Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 15/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19582802 | 0.85 | ACKR3 (0.54) | ACKR3KCNH2GRM2CHRM3 | |
| SCHEMBL16269334 | 0.81 | GRM5 (0.42) | ACKR3KCNH2GRM2 | |
| SCHEMBL19582537 | 0.78 | ACKR3 (0.57) | ACKR3 | |
| SCHEMBL17802019 | 0.77 | ACKR3 (0.58) | ACKR3 | |
| SCHEMBL19582548 | 0.77 | ACKR3 (0.44) | ACKR3KCNH2GRM2 | |
| SCHEMBL17801963 | 0.76 | ACKR3 (1.00) | ACKR3 | |
| SCHEMBL17801929 | 0.75 | ACKR3 (1.00) | ACKR3 | |
| SCHEMBL17801919 | 0.75 | ACKR3 (1.00) | ACKR3 | |
| SCHEMBL19582222 | 0.73 | GRM2 (0.53) | ACKR3KCNH2GRM2 | |
| SCHEMBL19582567 | 0.72 | ACKR3 (0.63) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001279-B | CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2020-10-20 | — | — | CN | disclosed |
| EP-3227263-B1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-10202368-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2019-02-12 | — | — | US | disclosed |
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-16 | — | — | US | disclosed |
| EP-3227263-A1 | CXCR7 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd (CH) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016087370-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202368-B2 | CXCR7 receptor modulators | CXCR1, CXCR5, CXCR2 | ACKR3 8/4885KCNH2 2619/4885GRM2 877/4885 |
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | ACKR3 9/4885KCNH2 2404/4885GRM2 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.